Altea starts diabetes and pain skin patch trials:
This article was originally published in Clinica
Altea Therapeutics has begun US clinical trials to test its noninvasive skin patch technology as a treatment for two conditions: diabetes and severe pain. The two phase I studies incorporate the Tucker, Georgia firm's proprietary PassPort system, developed to deliver protein and peptide drugs, small-molecule drugs, genes and vaccines across the skin for local and systemic effect. The first study is testing AT1391, a daily insulin skin patch for providing continuous basal levels of insulin in diabetics. The second is assessing AT1022, a hydromorphone skin patch for the rapid and sustained delivery of a potent opiate for managing severe pain.
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.